Live
- Siddaramaiah govt defends police action on Panchamasali Lingayat protesters
- India fined for slow over-rate in second WODI against Australia
- Former Bhimavaram MLA Grandhi Srinivas Resigns from YSRCP
- Nagaur MP raises questions on intelligence failure after Raj CM's convoy hit by car
- Bengal: Senior resident doctor accused of rape, attempt to murder absconding
- Prateeksha Srivastava says she seldom meets fellow music composers Rusha, Blizza, in person
- KTR Accuses Government of Brutality Against Farmers, Calls for Immediate Action
- Manchu Manoj Attends Shooting Amid Family Controversy
- BWF World Tour Finals: Treesa-Gayatri defeat Malaysian pair to keep semis hopes alive
- MUDA case: Complainant Krishna asks Lokayukta to file new plaint on CM Siddaramaiah on ED’s report
Glenmark Q4 net up 6% at Rs 233.87 crore
Glenmark Q4 net up 6% at Rs 233.87 crore
Drug firm Glenmark Pharmaceuticals has reported a 6.15 per cent rise in its consolidated net profit to Rs 233.87 crore for the quarter ended March 2021 on account of higher sales
Hyderabad: Drug firm Glenmark Pharmaceuticals has reported a 6.15 per cent rise in its consolidated net profit to Rs 233.87 crore for the quarter ended March 2021 on account of higher sales.
The company posted a net profit of Rs 220.30 crore in the corresponding period of the previous fiscal, Glenmark said in a statement on Friday.
Its consolidated revenue from operations stood at Rs 2,859.9 crore for the quarter under consideration. It was Rs 2,767.5 crore for the same period a year ago, it added.
For the fiscal ended March this year, the company posted a net profit of Rs 970.1 crore as against Rs 776 crore in the previous fiscal, Glenmark said.
The company's revenue from operations stood at Rs 10,943.9 crore for the fiscal ended March 2021. It was Rs 10,641 crore in 2019-20, it added.
"We delivered consistent performance dur ing the year despite operational challenges due to the Covid-19 pandemic. We led from the front in India's fight against the pandemic at its very onset, with our leading brand FabiFlu," Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said.
The company has in place strategic levers to grow its businesses sustainably, with a focus on strengthening its balance sheet, he added.
The company's board has recommended a dividend of Rs 2.50 per share for the financial year 2020-21, Glenmark said.
